
Purchase 1P-LSD
Discount program, second order - 5% OFF, third order - 7% OFF
With us securely! - re-shipment guarantees.
We always offer new legal products of impeccable quality.
Please make sure that the product is legal in your country and not under control before ordering.
We do not sell pharmaceutical products or controlled products.
Where to buy 1P-LSD for sale
1P-LSD is a psychedelic drug of the lysergamide class that is a derivative and functional analogue of LSD and a homolog of ALD-52.
1P-LSD is a psychedelic drug of the lysergamide class that is a derivative and homolog of LSD and an analogue of ALD-52. It is one of the series of lysergamides that have been sold as designer drugs since 2015.
1P-LSD is a psychedelic and hallucinogenic drug of the lysergamide class of chemicals. The chemical is essentially a homolog of LSD, being an analogue of ALD-52. 1P-LSD has been sold as a designer drug and research chemical online since 2015.
1P-LSD is a psychedelic derivative of lysergic acid diethylamide (LSD) that is sold for its psychedelic and entactogenic effects.
1P-LSD or 1-propionyl lysergic acid diethylamide is a naturally occurring psychedelic substance of the lysergamide chemical class that produces LSD-like psychedelic effects when administered.
1P-LSD is a chemical that is known to have characteristics of psychedelics.
1P-LSD is a psychoactive drug that acts as an agonist for the 5-HT2A receptor, but it has a unique mechanism of action that is not fully understood.
1P-LSD (1-propionyl-LSD) is a psychedelic drug sold online as a designer drug since 2015. It is an analogue of lysergic acid diethylamide (LSD), where the norleucine amide moiety has been propionylated to either the indole ring's 1- or 3- position. The IUPAC recommends the name 1-(1-(4-propionyloxyphenyl)ethyl)-N-propionylpropan-2-amine; however it is also known by its systematic name N-[1-[(1R,3S)-3-[(2R)-2-(methylamino)cyclohexyl]propyl]-4-propionyloxyphenyl]cyclopropane carboxamide
1P-LSD (1-propionyl-LSD) is a psychedelic drug sold online as a designer drug.
1P-LSD belongs to a class of chemicals known as lysergamides. It also is a derivative of lysergic acid diethylamide (LSD).
1P-LSD is a psychedelic lysergamide. It's a homolog and functional analogue of LSD and ALD-52 but with the molecular structure of 4-propionylmorpholine instead of 4-Bromo-2,5-dimethoxyamphetamine. First synthesized by Albert Hofmann in 1979, it was originally thought to be inactive until Alexander Shulgin performed human trials in 2012, which revealed that its effects are comparable to those of LSD
1P-LSD is a psychedelic lysergamide. This means that it's chemically similar to LSD and ALD-52, with a specific structural substitution on the carbon chain at R 6 and R 8 - propionyl-. Albert Hofmann first synthesized it in 1979, but its human activity was explored in 2012 by Alexander Shulgin. After these trials, we can confirm that it's comparable to LSD in terms of action.
1P-LSD is a psychedelic lysergamide of the lysergamide class, closely resembling the effects of LSD and ALD-52, differing only with a specific structural substitution on the carbon chain at R 6 and R 8 - propionyl-. Albert Hofmann first synthesized it in 1979.
1P-LSD is a psychedelic lysergamide of the lysergamide family. This means it's similar to LSD and ALD-52 but has a specific structural substitution on the carbon chain at R 6 and 8.
1P-LSD is a psychedelic lysergic acid diethylamide. It's chemically related to LSD and ALD-52 but with a propionyl substitution on the carbon chain at R 6 and 8 - meaning it's slightly shorter than LSD.
1P-LSD is an experimental psychedelic drug and is not intended for human consumption.
To prepare the content, the following materials were used:
- FDA Substance Registration System
- Hazardous Substances Data Bank. National Library of Medicine. 28 August 2008. Retrieved 22 August 2014. 3,4-Methylenedioxymethamphetamine
- Liver transplant modulates gut microbial dysbiosis and cognitive function in cirrhosis. PDF . By HoChong Gilles, Scott C Matherly, Mohammed S Siddiqui, Puneet Puri...
- Differential impact of hyponatremia and hepatic encephalopathy on health-related quality of life and brain metabolite abnormalities in cirrhosis . By Jasmohan Bajaj
- An overview of alcohol and other drug issues
- Medicating the mind: a Kantian analysis of overprescribing psychoactive drugs B A Manninen
- The pharmacological basis of opioids Carla Ghelardini, Lorenzo Di Cesare Mannelli and Enrica Bianchi
- Ask Dr. Shulgin Online ARCHIVE: June 3, 2004
- Inhibition of plasma membrane monoamine transporters by β-ketoamphetamines. Nicholas V Cozzi, Michael KSievert, Alexander T Shulgin, Peyton JacobIII, Arnold Eruoho
- Schedules of Controlled Substances: Placement of Methylone Into Schedule I
- Bioanalysis of new designer drugs. Wohlfarth A, Weinmann W.
- New Psychoactive Substances (including synthetic cannabinoids, mephedrone, and more)
- Future Synthetic Drugs of Abuse. Donald A. Cooper. Drug Enforcement Administration McLean, Virginia
- Designer drugs: a medicinal chemistry perspective. F. Ivy Carroll Anita H. Lewin S. Wayne Mascarella Herbert H. Seltzman P. Anantha Reddy
- Synthetic cannabinoids in Europe
- Pharmacological Effects of MDMA in Man. By Enno Freye
- Drug Use in Relation to Outcome of Mammography Screening. von Euler-Chelpin M, Wu W, Vejborg and Lynge E
- DEA Drug Scheduling
- Electrophysiological Effects of Trace Amines on Mesencephalic Dopaminergic Neurons.Ada Ledonne, Nicola Berretta, Alessandro Davoli, Giada Ricciardo Rizzo, Giorgio Bernardi and Nicola Biagio Mercuri
- Electrophysiological evidence for a reciprocal interaction between amphetamine and cocaine-related drugs on rat midbrain dopaminergic neurons.Scarponi M, Bernardi G, Mercuri NB.
- Overdose of Drugs for Attention-Deficit Hyperactivity Disorder: Clinical Presentation, Mechanisms of Toxicity, and Management. Henry A. Spiller, author Hannah L. Hays Alfred Aleguas.
- Dose-dependent effectiveness of wheel running to attenuate cocaine-seeking: impact of sex and estrous cycle in rats. Peterson AB, Hivick DP, Lynch WJ.r.
- FDA Drug Safety Communication: Safety Review Update of Medications used to treat Attention-Deficit/Hyperactivity Disorder (ADHD) in children and young adults
- ADHD Medications and Risk of Serious Cardiovascular Events in Young and Middle-aged Adults
- Controlled Substances Act
- The Art of Drug Synthesis (Wiley Series on Drug Synthesis)
- Cannabis: domestic cultivation widespread
- A review of the influence of functional group modifications to the core scaffold of synthetic cathinones on drug pharmacokinetics